Jump to Main Content
New evidence of exercise training benefits in myostatin-deficient mice: Effect on lipidomic abnormalities
- Baati, Narjes, Feillet-Coudray, Christine, Fouret, Gilles, Vernus, Barbara, Goustard, Bénédicte, Jollet, Maxence, Bertrand-Gaday, Christelle, Coudray, Charles, Lecomte, Jérôme, Bonnieu, Anne, Koechlin-Ramonatxo, Christelle
- Biochemical and biophysical research communications 2019 v.516 no.1 pp. 89-95
- cardiolipins, citrate (si)-synthase, exercise, gene expression regulation, genes, lipid composition, lipid metabolism, mice, mitochondria, mitochondrial membrane, muscle tissues, muscles, muscular atrophy, myostatin, protein content
- Myostatin (Mstn) inactivation or inhibition is considered as a promising treatment for various muscle-wasting disorders because it promotes muscle growth. However, myostatin-deficient hypertrophic muscles show strong fatigability associated with abnormal mitochondria and lipid metabolism. Here, we investigated whether endurance training could improve lipid metabolism and mitochondrial membrane lipid composition in mice where the Mstn gene was genetically ablated (Mstn−/- mice). In Mstn−/- mice, 4 weeks of daily running exercise sessions (65–70% of the maximal aerobic speed for 1 h) improved significantly aerobic performance, particularly the endurance capacity (up to +280% compared with untrained Mstn−/- mice), to levels comparable to those of trained wild type (WT) littermates. The expression of oxidative and lipid metabolism markers also was increased, as indicated by the upregulation of the Cpt1, Ppar-δ and Fasn genes. Moreover, endurance training also increased, but far less than WT, citrate synthase level and mitochondrial protein content. Interestingly endurance training normalized the cardiolipin fraction in the mitochondrial membrane of Mstn−/- muscle compared with WT. These results suggest that the combination of myostatin inhibition and endurance training could increase the muscle mass while preserving the physical performance with specific effects on cardiolipin and lipid-related pathways.